Researchers probe genetic link to blindness

September 8, 2011 in Ophthalmology

University of Leeds researchers have used next-generation DNA sequencing techniques to discover what causes a rare form of inherited eye disorders, including cataracts and glaucoma, in young children.

The findings should make it easier to identify families with this condition who are at risk of conceiving children with severely impaired vision, so they can receive appropriate genetic counselling. The work, co-led with colleagues at Flinders University in Adelaide, Australia, may also lead to new treatments for adults and children with this form of inherited blindness.

The researchers looked at DNA from three unrelated families. All families had members with a history of from birth, linked to problems with the eye's lens and cornea. Together, the lens and cornea make up the clear 'window' at the front of the eye. But if these structures do not develop correctly then this 'window' can become cloudy, making it difficult to see clearly. If the problems are not treated, they can get worse leading to and eventually blindness.

Dr Manir Ali and colleagues discovered that all of the various family members with impaired vision had defects in an antioxidant protein known as peroxidasin that makes up part of the lens and cornea. They concluded that these defects are responsible for causing cataracts and glaucoma in children with this rare form of inherited eye disorders.

"We know that in healthy eyes, peroxidasin acts as a first line of defence against the damage that and sunlight does to our skin. It may also help protect against in older people," Dr Ali said. "Our findings imply that this same protein is essential for the normal development of the lens and surrounding structures at the front of the eye."

Full details of the study are published in the latest issue of the .

The discovery was made using next generation DNA sequencing, a new way of reading genes quickly and spotting errors that cause inherited diseases. Dr Ali and colleague now plan to use the same approach to screen all the eyes genes at once, so that all patients with inherited blindness can find out exactly what is causing their illness and can be given the appropriate treatment.

"This DNA sequencing technology looks set to revolutionise the medical world, giving patients and their doctors more information than ever before about their genetic make-up and how it can affect their health and response to treatment," Dr Ali said.

More information: The paper, 'Homozygous mutations in peroxidasin (PXDN) cause congenital cataract, corneal opacity and developmental glaucoma', is published online in the American Journal of Human Genetics (DOI 10.1016/j.ajhg.2011.08.005).

Provided by University of Leeds search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Glaucoma drug can cause droopy eyelids

Prostaglandin analogues (PGAs), drugs which lower intraocular pressure, are often the first line of treatment for people with glaucoma, but their use is not without risks. PGAs have long been associated with blurred vision, ...

Ophthalmology created 12 hours ago | popularity not rated yet | comments 0

Eyes on the sun: Child sunshine exposure and eye development

(Medical Xpress)—Exposure to sunshine as a small child is crucial to the development of a healthy eye according to results of long-term myopia study conducted by University of Sydney researchers.

Ophthalmology created 17 hours ago | popularity 5 / 5 (1) | comments 0

New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery

The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...

Ophthalmology created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast

Early screenings key to diagnosing glaucoma

New research is emphasizing the importance of regular screenings for glaucoma, a disease that deteriorates the optic nerve over time and is a leading cause of irreversible blindness worldwide. The onset of glaucoma is associated ...

Ophthalmology created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast

University partners with Sony to find cure for 'lazy eye'

The University of Nottingham and Nottingham University Hospitals NHS Trust, have been working with Sony Computer Entertainment Europe (SCEE) to develop special 3-D glasses and games to help treat children ...

Ophthalmology created May 08, 2013 | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.